Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QH103 in Refractory Autoimmune Diseases
NCT06828042Phase 2Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of QH103E in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's syndrome, Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), inflammatory myopathy (IIM), sponsored by Peking University Third Hospital. Started Jul 2025; status: recruiting.
02
Drugs
QH103E
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)Sjögren's syndromeAntineutrophil cytoplasmic antibody-associated vasculitis (AAV)inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT06828042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06828042.